PL3344655T3 - Zastosowanie przeciwciał anty-cd40 w leczeniu toczniowego zapalenia nerek - Google Patents

Zastosowanie przeciwciał anty-cd40 w leczeniu toczniowego zapalenia nerek

Info

Publication number
PL3344655T3
PL3344655T3 PL16763663.8T PL16763663T PL3344655T3 PL 3344655 T3 PL3344655 T3 PL 3344655T3 PL 16763663 T PL16763663 T PL 16763663T PL 3344655 T3 PL3344655 T3 PL 3344655T3
Authority
PL
Poland
Prior art keywords
antibodies
treatment
lupus nephritis
nephritis
lupus
Prior art date
Application number
PL16763663.8T
Other languages
English (en)
Inventor
Scott Ronald Brodeur
Thomas B. Freeman
Gerald Henry NABOZNY
Meera RAMANUJAM
Paul SCHOLL
Juergen STEFFGEN
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of PL3344655T3 publication Critical patent/PL3344655T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16763663.8T 2015-09-01 2016-08-31 Zastosowanie przeciwciał anty-cd40 w leczeniu toczniowego zapalenia nerek PL3344655T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US201662287587P 2016-01-27 2016-01-27
PCT/US2016/049558 WO2017040566A1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
PL3344655T3 true PL3344655T3 (pl) 2024-02-19

Family

ID=56896810

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16763663.8T PL3344655T3 (pl) 2015-09-01 2016-08-31 Zastosowanie przeciwciał anty-cd40 w leczeniu toczniowego zapalenia nerek

Country Status (16)

Country Link
US (3) US20170058038A1 (pl)
EP (1) EP3344655B1 (pl)
JP (2) JP2018529661A (pl)
KR (1) KR20180039172A (pl)
CN (1) CN107922501A (pl)
AU (1) AU2016317028B2 (pl)
BR (1) BR112018001907A2 (pl)
CA (1) CA2993996A1 (pl)
CL (1) CL2018000317A1 (pl)
DK (1) DK3344655T5 (pl)
ES (1) ES2969968T3 (pl)
HU (1) HUE063528T2 (pl)
MX (1) MX390653B (pl)
PH (1) PH12018500445B1 (pl)
PL (1) PL3344655T3 (pl)
WO (1) WO2017040566A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
US20200299400A1 (en) * 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
AU2019291890A1 (en) * 2018-06-29 2020-12-17 Boehringer Ingelheim International Gmbh Anti-CD40 antibodies for use in treating autoimmune disease
MX2021006360A (es) * 2018-11-30 2021-08-11 Jiangsu Hengrui Medicine Co Composicion farmaceutica de anticuerpo cd40 y uso de la misma.
RS66868B1 (sr) 2021-01-28 2025-06-30 Regeneron Pharma Kompozicije i postupci za lečenje sindroma oslobađanja citokina
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
AU2005323515A1 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
EP1885399B1 (en) * 2005-05-26 2010-10-20 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
GEP20125628B (en) * 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
NZ602020A (en) 2010-03-31 2014-05-30 Boehringer Ingelheim Int Anti-cd40 antibodies
ES2709654T3 (es) * 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
CL2018000317A1 (es) 2018-07-20
MX2018002447A (es) 2018-06-15
MX390653B (es) 2025-03-21
HUE063528T2 (hu) 2024-01-28
EP3344655B1 (en) 2023-07-26
CN107922501A (zh) 2018-04-17
US20170058038A1 (en) 2017-03-02
DK3344655T5 (da) 2024-10-07
WO2017040566A1 (en) 2017-03-09
US20190177420A1 (en) 2019-06-13
JP2021185169A (ja) 2021-12-09
AU2016317028B2 (en) 2021-09-09
BR112018001907A2 (pt) 2018-09-25
PH12018500445B1 (en) 2022-08-10
US20230265203A1 (en) 2023-08-24
EP3344655A1 (en) 2018-07-11
JP2018529661A (ja) 2018-10-11
AU2016317028A1 (en) 2018-02-22
CA2993996A1 (en) 2017-03-09
KR20180039172A (ko) 2018-04-17
DK3344655T3 (da) 2023-10-09
ES2969968T3 (es) 2024-05-23
PH12018500445A1 (en) 2018-09-10

Similar Documents

Publication Publication Date Title
ZA201708448B (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
IL253802A0 (en) A preparation for the treatment of osteoporosis
IL252568A0 (en) Anti-cd38 antibodies for the treatment of acute myeloid leukemia
ZA201703585B (en) Combination immunotherapy approach for treatment of cancer
DK3143025T3 (da) Forbindelser til behandling af spinal muskelatrofi
IL252309B (en) Compressed bicyclic compounds for disease treatment
IL285077A (en) Compounds for the treatment of cancer
IL252849A0 (en) Compressed bicyclic compounds for disease treatment
EP3137087A4 (en) Estrogen combination for treatment of multiple sclerosis
PT3236960T (pt) Fluralaner para utilização no tratamento da demodicose
IL258593A (en) Compounds for the treatment of subculture disorders
IL248697A0 (en) Methods for purifying antibodies
HUE063528T2 (hu) Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére
IL247954A0 (en) Immunoglobulin mobilisation
PT3662925T (pt) Composição compreendendo fsh para o tratamento da infertilidade
ZA201907460B (en) Improved protocol for treatment of lupus nephritis
GB201609314D0 (en) Methods of forming compounds
EP3137089A4 (en) Use of ginsenoside m1 for treating lupus nephritis
IL246540A0 (en) Freezeald receptor antibodies for cancer treatment
ZA201704589B (en) Compounds for the treatment of cancer
GB201418268D0 (en) Composition & methods of treatment
GB201418272D0 (en) Composition & methods of treatment
GB201418773D0 (en) Mechanism of action